• Citer

Leukemia

par Vallois, David;Missiaglia, Edoardo;Veloza, Luis;Fischer, Anja;Cavalieri, Doriane;Rattina, Vimel;Bisig, Bettina;Roh, Vincent;Wiehle, Laura;Sarkis, Rita;Bachy, Emmanuel;Bonnet, Christophe;Bruneau, Julie;Cairoli, Anne;De Wind, Roland;Drieux, Fanny;Dubois, Romain;Emile, Jean-François;Fataccioli, Virginie;Laribi, Kamel;Ledoux-Pilon, Albane;Lemonnier, François;Llamas-Gutierrez, Francisco;Morel, Pierre ;Parrens, Marie;Poullot, Elsa;Quintanilla-Martinez, Leticia;Sandrini, Jeremy;Somja, Joan;Xerri, Luc;Tournilhac, Olivier;Gaulard, Philippe;Siebert, Reiner;de Leval, Laurence
Référence Leukemia
Publication Publié, 2025

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Correction to: Leukemiahttps://doi.org/10.1038/s41375-025-02777-2, published online 07 October 2025 In the originally published version of this article, same minor errors were present: (1) in Table 1, only the headers should appear in bold font, as now corrected; (2) in Figure 1B, two typographical errors occurred in panels c and d, where the correct legends are MEITL No 030 and MEITL No 039 instead of EATL No 030 and EATL No 039; (3) in Figure 3B, the MEITL CNV profile was mistakenly replaced by a duplication of the EATL profile. The correct MEITL profile has been now inserted; (4) in Figure 4F, the miRNA “577” label appeared in green font instead of black. All errors have been corrected in the revised figures and table provided in the updated version. Incorrect figure 1 (Figure presented.) Corrected figure 1 (Figure presented.) Incorrect figure 3 (Figure presented.) Corrected figure 3 (Figure presented.) Incorrect figure 4 (Figure presented.) Corrected figure 4 (Figure presented.) (Table presented.) MEITL (n = 52) EATL (n = 30) p value Reported celiac disease 0/52 (0%) 13/30 (43%) Age, median, years (range, median) 67 (29-91) 64 (34-86) 0.37 Gender (male/female) 27:25:00 19:11 0.2 Acute event at presentation 38/44 (86%) 12/18 (67%) 0.09 Bowel perforation 33/44 (75%) 8/18 (44%) Bowel obstruction 12/44 (27%) 6/18 (33%) 0.76 Lugano stage Stage I/II 27/44 (61%) 8/13 (61%) 1 Stage III/IV 17/44 (39%) 5/13 (39%) PS 0-1 18/40 (45%) 4/8 (50%) 1 ≥2 22/40 (55%) 4/8 (50%) Typical 31/52 (60%) Atypical 21/52 (40%) Pleomorphic 13/52 (25%) 30/30 (100%) Anaplastic 1/52 (2%) 15/30 (50%) Necrosis 7/52 (13%) 22/30 (73%) Starry-sky 5/52 (10%) 3/30 (10%) 1 Angiotropism 14/51 (27%) 19/29 (65%) Epitheliotropism 36/41 (88%) 2/20 (10%) Moderate/abundant inflammation 3/52 (6%) 20/30 (67%) CD8 47/52 (90%) 4/30 (13%) CD56 46/52 (88%) 2/28 (7%) CD3 52/52 (100%) 27/30 (90%) CD2 20/47 (42%) 12/24 (50%) 0.619 CD5 2/51 (4%) 2/30 (7%) 0.624 CD7 48/48 (100%) 22/23 (96%) 0.324 CD4 2/52 (4%) 2/27 (7%) 0.603 CD103 40/51 (78%) 15/25 (60%) 0.108 CD30 0/47 (0%) 25/29 (86%) TIA1 47/52 (90%) 20/25 (80%) 0.108 Granzyme B 37/52 (71%) 19/28 (68%) 0.596 Perforin 27/52 (52%) 22/29 (76%) CD20 9/49 (18%) 1/29 (3%) CD79a 3/41 (7%) 0/10 (0%) 0.567 TCRβ 17/50 (34%) 8/28 (29%) 0.472 TCRγδ 26/50 (52%) 8/27 (30%) TCRαβ-TCRγδ+ 22/49 (44%) 4/26 (15%) TCRαβ+TCRγδ- 12/49 (24%) 4/26 (15%) 0.391 TCRαβ+TCRγδ+ 4/49 (8%) 3/26 (11%) 0.685 TCRαβ-TCRγδ- 11/49 (22%) 15/26 (58%) The original article has been corrected.